References
Body Weight (BMI) and Cancer
1.) Lim U, Morton LM, Subar AF,
Baris D, Stolzenberg-Solomon R, Leitzmann M, Kipnis V, Mouw T, Carroll L,
Schatzkin A, Hartge P.Alcohol, smoking, and body size in relation to incident
Hodgkin's and non-Hodgkin's lymphoma risk. Am J Epidemiol. 2007 Sep
15;166(6):697-708. Epub 2007 Jun 27.
2.) Maskarinec G, Erber E, Gill J, Cozen W, Kolonel LN. Overweight and Obesity
at Different Times in Life as Risk Factors for Non-Hodgkin's Lymphoma: The
Multiethnic Cohort. Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):196-203.
Epub 2008 Jan 9.
3.) Máchová L, Cízek L, Horáková D, Koutná J, Lorenc J, Janoutová G, Janout V.
Association between obesity and cancer incidence in the population of the
District Sumperk, Czech Republic. Onkologie. 2007 Nov;30(11):538-42. Epub 2007
Nov 8.
4.) Dai Z, Xu YC, Niu L. Obesity and colorectal cancer risk: a meta-analysis of
cohort studies. World J Gastroenterol. 2007 Aug 21;13(31):4199-206.
5.) Ahn J, Schatzkin A, Lacey JV Jr, Albanes D, Ballard-Barbash R, Adams KF,
Kipnis V, Mouw T, Hollenbeck AR, Leitzmann MF. Adiposity, adult weight change,
and postmenopausal breast cancer risk. Arch Intern Med. 2007 Oct
22;167(19):2091-102.
6.) Chiu BC, Gapstur SM, Greenland P, Wang R, Dyer A.
Body mass index, abnormal glucose metabolism, and mortality from hematopoietic
cancer.Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2348-54.
7.) Pischon T, Lahmann PH, Boeing H,et al. Body size and risk of colon and
rectal cancer in the European Prospective Investigation Into Cancer and
Nutrition (EPIC). J Natl Cancer Inst. 2006 Jul 5;98(13):920-31.
8.) Pan SY, Johnson KC, Ugnat AM, Wen SW, Mao Y; Canadian Cancer Registries
Epidemiology Research Group. Association of obesity and cancer risk in Canada.
Am J Epidemiol. 2004 Feb 1;159(3):259-68.
9.) Moore LL, Bradlee ML, Singer MR, Splansky GL, Proctor MH, Ellison RC, Kreger
BE. Int J Obes Relat Metab Disord. 2004 Apr;28(4):559-67.BMI and waist
circumference as predictors of lifetime colon cancer risk in Framingham Study
adults.
10.) Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and
mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J
Med. 2003 Apr 24;348(17):1625-38
11.) Wolk A, Gridley G, Svensson M, Nyrén O, McLaughlin JK, Fraumeni JF, Adam
HO. A prospective study of obesity and cancer risk (Sweden).Cancer Causes
Control. 2001 Jan;12(1):13-21.
12.) Andersson S-O, Wolk A, Bergstrom R, et al. Body size and prostate cancer: a
20-year follow-up study among 135,006 Swedish construction workers. J Natl
Cancer Inst 1997;89:385–9.
13.) Talamini R, La Vecchia C, Decarli A, et al. Nutrition, social factors and
prostatic cancer in a Northern Italian population. Br J Cancer 1986;53:817–21.
Super Foods
1.) Khan N, Afaq F, Mukhtar H. Cancer Chemoprevention Through
Dietary Antioxidants: Progress and Promise. Antioxid Redox Signal. 2007 Dec 21 [Epub
ahead of print].
2.) Moreno DA, López-Berenguer C, García-Viguera C. Effects of stir-fry cooking
with different edible oils on the phytochemical composition of broccoli. J Food
Sci. 2007 Jan;72(1):S064-8.
3.) Cohen JH, Kristal AR, Stanford JL. Fruit and vegetable intakes and prostate
cancer risk. J Natl Cancer Inst 2000;92(1):61–8.
4.) Cohen JH, Kristal AR, Stanford JL. Fruit and vegetable intakes and prostate
cancer risk. J Natl Cancer Inst 2000;92(1):61–8.
5.) Kune GA. Eating fish protects against some cancers: epidemiological and
experimental evidence for a hypothesis. J Nutr Med 1990;1:139–44 [review].
6.) Rose DP, Connolley JM. Omega-3 fatty acids as cancer chemopreventive agents.
Pharmacol Ther 1999;83:217–44.
7.) Demark-Wahnefried W, Price DT, Polascik TJ, et al. Pilot study of dietary
fat restriction and flaxseed supplementation in men with prostate cancer before
surgery: exploring the effects on hormonal levels, prostate-specific antigen,
and histopathologic features. Urology2001;58:47–52.
8.) Davis JN, Singh B, Bhuiyan M, Sarkar FH. Genistein-induced upregulation of
p21WAF1, downregulation of cyclin B, and induction of apoptosis in prostate
cancer cells. Nutr Cancer 1998;32:123–31.
9.) Barnes S, Peterson TG, Coward L. Rationale for the use of genistein-containing
soy matrices in chemoprevention trials for breast and prostate cancer. J Cell
Biochem Suppl 1995;22:181–7.
10.) Jacobsen BK, Knutsen SF, Fraser GE. Does high soy milk intake reduce
prostate cancer incidence? The Adventist Health Study (United States). Cancer
Causes Control 1998;9:553–7.
11.) Geller J, Sionit L, Partido C, et al. Genistein inhibits the growth of
human-patient BPH and prostate cancer in histoculture. Prostate 1998;34:75–9.
Smoking, Alcohol and Cancer Risk
1.) Kaufman EL, Jacobson JS, Hershman DL, Desai M, Neugut AI.
Effect of breast cancer radiotherapy and cigarette smoking on risk of second
primary lung cancer. J Clin Oncol. 2008 Jan 20;26(3):392-8.
2.) Park SM, Lim MK, Jung KW, Shin SA, Yoo KY, Yun YH, Huh BY. Prediagnosis
smoking, obesity, insulin resistance, and second primary cancer risk in male
cancer survivors: National Health Insurance Corporation Study. J Clin Oncol.
2007 Oct 20;25(30):4835-43.
3.) Koskinen WJ, Brřndbo K, Mellin Dahlstrand H, Luostarinen T, Hakulinen T,
Leivo I, Molijn A, Quint WG, Rřysland T, Munck-Wikland E, Mäkitie AA, Pyykkö I,
Dillner J, Vaheri A,
Aaltonen LM. Alcohol, smoking and human papillomavirus in laryngeal carcinoma: a
Nordic prospective multicenter study. J Cancer Res Clin Oncol. 2007
Sep;133(9):673-8. Epub 2007 May 8.
4.) Muwonge R, Ramadas K, Sankila R, Thara S, Thomas G, Vinoda J,
Sankaranarayanan R. Role of tobacco smoking, chewing and alcohol drinking in the
risk of oral cancer in Trivandrum, India: A nested case-control design using
incident cancer cases. Oral Oncol. 2007 Oct 12
5.) Chen CH, Shun CT, Huang KH, Huang CY, Tsai YC, Yu HJ, Pu YS. Stopping
smoking might reduce tumour recurrence in nonmuscle-invasive bladder cancer. BJU
Int. 2007 Aug;100(2):281-6; discussion 286. Epub 2007 Apr 5.
6.) Rieck G, Fiander A.The effect of lifestyle factors on gynaecological cancer.
Best Pract Res Clin Obstet Gynaecol. 2006 Apr;20(2):227-51.
7.) Ford MB, Sigurdson AJ, Petrulis ES, Ng CS, Kemp B, Cooksley
C, McNeese M, Selwyn BJ, Spitz MR, Bondy ML.Effects of smoking and radiotherapy
on lung carcinoma in breast carcinoma survivors. Cancer. 2003 Oct 1;98(7):1457-64.
8.) van Leeuwen FE, Klokman WJ, Stovall M, Hagenbeek A, van den Belt-Dusebout
AW, Noyon R, Boice JD Jr, Burgers JM, Somers R. Roles of radiotherapy and
smoking in lung cancer following Hodgkin's disease. J Natl Cancer Inst. 1995 Oct
18;87(20):1530-7.
9.) Neugut AI, Murray T, Santos J, Amols H, Hayes MK, Flannery JT, Robinson E.
Increased risk of lung cancer after breast cancer radiation therapy in cigarette
smokers. Cancer. 1994 Mar
15;73(6):1541-3.
10.) Day GL, Blot WJ, Shore RE, McLaughlin JK, Austin DF, Greenberg RS, Liff JM,
Preston-Martin S, Sarkar S, Schoenberg JB, et al. Second cancers following oral
and pharyngeal cancers: role of tobacco and alcohol. J Natl Cancer Inst. 1994
Jan 19;86(2):131-7.
11.) Day GL, Shore RE, Blot WJ, McLaughlin JK, Austin DF, Greenberg RS, Liff JM,
Preston-Martin S, Sarkar S, Schoenberg JB, et al. Dietary factors and second
primary cancers: a follow-up of oral and pharyngeal cancer patients. Nutr
Cancer. 1994;21(3):223-32.
Drinking Water and Cancer Risk
1.) Richardson SD, Plewa MJ, Wagner ED, Schoeny R,
Demarini DM. Occurrence, genotoxicity, and carcinogenicity of regulated and
emerging disinfection by-products in drinking water: a review and roadmap for
research. Mutat Res. 2007 Nov-Dec;636(1-3):178-242. Epub 2007 Sep 12.
2.) Kasim K, Levallois P, Johnson KC, Abdous B, Auger P; Canadian Cancer
Registries Epidemiology Research Group. Chlorination disinfection by-products in
drinking water and the risk of adult leukemia in Canada. Am J Epidemiol. 2006
Jan 15;163(2):116-26. Epub 2005 Nov 30.
3.) Do MT, Birkett NJ, Johnson KC, Krewski D, Villeneuve P; Canadian Cancer
Registries Epidemiology Research Group. Chlorination disinfection by-products
and pancreatic cancer risk.
Environ Health Perspect. 2005 Apr;113(4):418-24.
4.) Cancer Causes Control. 1996 Nov;7(6):596-604. Drinking water source and
chlorination byproducts in Iowa. III. Risk of brain cancer. Am J Epidemiol. 1999
Sep 15;150(6):552-60.
5.) Wigle DT. Safe drinking water: a public health challenge. Chronic Dis Can.
1998;19(3):103-7. Review.
6.) Cantor KP, Lynch CF, Hildesheim ME, Dosemeci M, Lubin J, Alavanja M, Craun
G.Drinking water source and chlorination byproducts. I. Risk of bladder cancer.
Epidemiology. 1998 Jan;9(1):21-8.
7.) King WD, Marrett LD. Case-control study of bladder cancer and chlorination
by-products in treated water (Ontario, Canada). Cancer Causes Control. 1996
Nov;7(6):596-604.
Exercise and Cancer
1.) Valenti M, Porzio G, Aielli F, Verna L, Cannita K, Manno R,
Masedu F, Marchetti P, Ficorella C.Physical exercise and quality of life in
breast cancer survivors. Int J Med Sci. 2008 Jan 15;5(1):24-8.
2.) Greenspan SL. Approach to the prostate cancer patient with bone disease. J
Clin Endocrinol Metab. 2008 Jan;93(1):2-7.
3.) Farrell SW, Cortese GM, Lamonte MJ, Blair SN.Cardiorespiratory fitness,
different measures of adiposity, and cancer mortality in men.Obesity (Silver
Spring). 2007 Dec;15(12):3140-9.
4.) McBride D. Healthful eating and exercise may lower mortality after
breast cancer. ONS Connect. 2007 Dec;22(12):27.
5.) Karvinen KH, Courneya KS, North S, Venner P. Associations between
exercise and quality of life in bladder cancer survivors: a population-based
study.Cancer Epidemiol Biomarkers Prev. 2007 May;16(5):984-90.
6.) Kruk J. Physical activity in the prevention of the most frequent chronic
diseases: an analysis of the recent evidence. Asian Pac J Cancer Prev. 2007
Jul-Sep;8(3):325-38.
7.) Lynch BM, Cerin E, Owen N, Aitken JF. Associations of leisure-time physical
activity with quality of life in a large, population-based sample of colorectal
cancer survivors. Cancer Causes Control. 2007 Sep;18(7):735-42. Epub 2007 May
23.
8.) Milne HM, Gordon S, Guilfoyle A, Wallman KE, Courneya KS. Association
between physical activity and quality of life among Western Australian breast
cancer survivors. Psychooncology. 2007 Dec;16(12):1059-68.
9.) Stevinson C, Faught W, Steed H, Tonkin K, Ladha AB, Vallance JK, Capstick V,
Schepansky A, Courneya KS.Associations between physical activity and quality of
life in ovarian cancer survivors. Gynecol Oncol. 2007 Jul;106(1):244-50. Epub
2007 May 9.
10.) Chang SC, Ziegler RG, Dunn B, Stolzenberg-Solomon R, Lacey
JV Jr, Huang WY, Schatzkin A, Reding D, Hoover RN, Hartge P, Leitzmann MF.
Association of energy intake and energy balance with postmenopausal breast
cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.
Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):334-41.
11.) Rogers LQ, Courneya KS, Robbins KT, Malone J, Seiz A, Koch L, Rao K,
Nagarkar M. Physical activity and quality of life in head and neck cancer
survivors. 1: Support Care Cancer. 2006 Oct;14(10):1012-9. Epub 2006 Mar 15.
12.) Hanna L, Adams M. Prevention of ovarian cancer. Best Pract Res Clin Obstet
Gynaecol. 2006 Apr;20(2):339-62. Epub 2005 Dec 20.
13.) Pan SY, Ugnat AM, Mao Y. Physical activity and the risk of ovarian cancer:
a case-control study in Canada. Int J Cancer. 2005 Nov 1;117(2):300-7.
14.) Courneya KS, Karvinen KH, Campbell KL, Pearcey RG, Dundas G, Capstick
V, Tonkin KS. Associations among exercise, body weight, and quality of life in a
population-based sample of endometrial cancer survivors. Gynecol Oncol. 2005
May;97(2):422-30.
15.) Vallance JK, Courneya KS, Jones LW, Reiman T. Differences in quality of
life between non-Hodgkin's lymphoma survivors meeting and not meeting public
health exercise guidelines. Psychooncology. 2005 Nov;14(11):979-91.
16.) Zhang M, Xie X, Lee AH, Binns CW.Sedentary behaviours and epithelial
ovarian cancer risk. Cancer Causes Control. 2004 Feb;15(1):83-9.
Emotional Hygiene and The immune System
1.) Chandrashekara S, Jayashree K, Veeranna HB,
Vadiraj HS, Ramesh MN, Shobha A, Sarvanan Y, Vikram YK. Effects of anxiety on
TNF-alpha levels during psychological stress. J Psychosom Res. 2007
Jul;63(1):65-9.
2.) Witek-Janusek L, Gabram S, Mathews HL.Psychologic stress, reduced NK cell
activity, and cytokine dysregulation in women experiencing diagnostic breast
biopsy. Psychoneuroendocrinology. 2007 Jan;32(1):22-35. Epub 2006 Nov 7.
3.) Di Donato A, Di Giampaolo L, Reale M, Dadorante V, Alparone F, Stocchi M,
Fattorini E, Di Gioacchino M, Magrini A, Boscolo P. Effect of occupational
stress and anxiety on natural killer lymphocyte activity of men and women
employed in a university. Int J Immunopathol Pharmacol. 2006 Oct-Dec;19(4 Suppl):79-84.
4.) Barak Y. The immune system and happiness. Autoimmun Rev. 2006
Oct;5(8):523-7. Epub 2006 Mar 21.
5.) Ickovics JR, Milan S, Boland R, Schoenbaum E, Schuman P, Vlahov D; HIV
Epidemiology Research Study (HERS) Group.Psychological resources protect health:
5-year survival and immune function among HIV-infected women from four US
cities. AIDS. 2006 Sep 11;20(14):1851-60.
6.) Rosenkranz MA, Jackson DC, Dalton KM, Dolski I, Ryff CD, Singer BH, Muller
D, Kalin NH, Davidson RJ. Affective style and in vivo immune response:
neurobehavioral mechanisms. Proc Natl Acad Sci U S A. 2003 Sep
16;100(19):11148-52. Epub 2003 Sep 5.
Multiple Vitamins and Cancer
1.) Simone CB 2nd, Simone NL, Simone V, Simone CB. Antioxidants
and other nutrients do not interfere with chemotherapy or radiation therapy and
can increase kill and increase survival,
part 1. Altern Ther Health Med. 2007 Jan-Feb;13(1):22-8.
2.) Simone CB 2nd, Simone NL, Simone V, Simone CB. Antioxidants and other
nutrients do not interfere with chemotherapy or radiation therapy and can
increase kill and increase survival,
Part 2. Altern Ther Health Med. 2007 Mar-Apr;13(2):40-7.
3.) Tsao SM, Yin MC, Liu WH. Oxidant stress and B vitamins status in patients
with non-small cell lung cancer. Nutr Cancer. 2007;59(1):8-13.
4.) Moss RW. Should patients undergoing chemotherapy and radiotherapy be
prescribed antioxidants? Integr Cancer Ther. 2006 Mar;5(1):63-82.
5.) Moyad MA. The use of complementary/preventive medicine to prevent prostate
cancer recurrence/progression following definitive therapy. Part II--rapid
review of dietary supplements.
Curr Opin Urol. 2003 Mar;13(2):147-51.
6.) Moyad MA. Potential lifestyle and dietary supplement options for the
prevention and postdiagnosis of bladder cancer. Urol Clin North Am. 2002
Feb;29(1):31-48, viii.
7.) Kamat AM, Lamm DL. Diet and nutrition in urologic cancer. W V Med J. 2000
May-Jun;96(3):449-54.
9.) Jatoi A, Daly BD, Kramer G, Mason JB. A cross-sectional study
of vitamin intake in postoperative non-small cell lung cancer patients. J Surg
Oncol 1998;68:231–6.
10.) Jatoi A, Daly BD, Kramer G, Mason JB. A cross-sectional study of vitamin
intake in postoperative non-small cell lung cancer patients. J Surg Oncol
1998;68:231–6.
11.) Lamm DL, Riggs DR, Shriver JS, vanGilder PF, Rach JF, DeHaven JI. Megadose
vitamins in bladder cancer: a double-blind clinical trial. J Urol. 1994
Jan;151(1):21-6.
Antioxidants (General) and Cancer
1.) Simone CB 2nd, Simone NL, Simone V, Simone CB. Antioxidants
and other nutrients do not interfere with chemotherapy or radiation therapy and
can increase kill and increase survival, part 1. Altern Ther Health Med. 2007
Jan-Feb;13(1):22-8.
2.) Simone CB 2nd, Simone NL, Simone V, Simone CB. Antioxidants and other
nutrients do not interfere with chemotherapy or radiation therapy and can
increase kill and increase survival, Part 2. Altern Ther Health Med. 2007
Mar-Apr;13(2):40-7.
3.) Kirsh VA, Hayes RB, Mayne ST, Chatterjee N, Subar AF, Dixon LB, Albanes D,
Andriole GL, Urban DA, Peters U; PLCO Trial. Supplemental and dietary vitamin E,
beta-carotene, and vitamin C intakes and prostate cancer risk.J Natl Cancer
Inst. 2006 Feb 15;98(4):245-54.
4.) Berger MM. Can oxidative damage be treated nutritionally? Clin Nutr. 2005
Apr;24(2):172-83.
5.) Ferguson LR, Philpott M, Karunasinghe N. Dietary cancer and prevention using
antimutagens. Toxicology. 2004 May 20;198(1-3):147-59.
6.) Borek C. Dietary antioxidants and human cancer.Integr Cancer Ther. 2004
Dec;3(4):333-41.
7.) Prasad KN. Multiple dietary antioxidants enhance the efficacy of standard
and experimental cancer therapies and decrease their toxicity. Integr Cancer
Ther. 2004 Dec;3(4):310-22.
8.) Heyland DK, Dhaliwal R, Suchner U, Berger MM. Antioxidant nutrients: a
systematic review of trace elements and vitamins in the critically ill patient.
Intensive Care Med. 2005 Mar;31(3):327-37. Epub 2004 Dec 17.
9.) Kim YT, Kim JW, Choi JS, Kim SH, Choi EK, Cho NH. Relation between deranged
antioxidant system and cervical neoplasia. Int J Gynecol Cancer. 2004
Sep-Oct;14(5):889-95.
10.) Drisko JA, Chapman J, Hunter VJ. The use of antioxidant therapies during
chemotherapy. Gynecol Oncol. 2003 Mar;88(3):434-9.
11.) Prasad KN, Cole WC, Kumar B, Prasad KC. Scientific rationale for using
high-dose multiple micronutrients as an adjunct to standard and experimental
cancer therapies. J Am Coll Nutr. 2001 Oct;20(5Suppl):450S-463S; discussion
473S-475S.
12.) Lamson DW, Brignall MS. Antioxidants in cancer therapy; their actions and
interactions with oncologic therapies. Altern Med Rev. 1999 Oct;4(5):304-29.
13.) Prasad KN, Kumar A, Kochupillai V, Cole WC. High doses of multiple
antioxidant vitamins: essential ingredients in improving the efficacy of
standard cancer therapy. J Am Coll Nutr. 1999
Feb;18(1):13-25.
14.) Lupulescu A. The role of vitamins A, beta-carotene, E and C
in cancer cell biology. Int J Vitam Nutr Res. 1994;64(1):3-14.
15.) Stähelin HB. Critical reappraisal of vitamins and trace minerals in
nutritional support of cancer patients. Support Care Cancer. 1993
Nov;1(6):295-7.
Vitamin A and Carotenes
1.) Yuan JM, Ross RK, Gao YT, Qu YH, Chu XD, Yu MC. Prediagnostic
levels of serum micronutrients in relation to risk of gastric cancer in
Shanghai, China. Cancer Epidemiol Biomarkers Prev. 2004 Nov;13(11 Pt 1):1772-80.
2.) Wu K, Erdman JW Jr, Schwartz SJ, Platz EA, Leitzmann M, Clinton SK, DeGroff
V, Willett WC, Giovannucci E.Plasma and dietary carotenoids, and the risk of
prostate cancer: a nested case-control study. Cancer Epidemiol Biomarkers Prev.
2004 Feb;13(2):260-9.
3.) Kamat AM, Lamm DL. Chemoprevention of bladder cancer. Urol Clin North Am.
2002 Feb;29(1):157-68.
4.) Sato R, Helzlsouer KJ, Alberg AJ, Hoffman SC, Norkus EP, Comstock GW.
Prospective study of carotenoids, tocopherols, and retinoid concentrations and
the risk of breast cancer. Cancer
Epidemiol Biomarkers Prev. 2002 May;11(5):451-7.
5.) Gann PH, Ma J, Giovannucci E, Willett W, Sacks FM, Hennekens CH,Stampfer MJ.
Lower prostate cancer risk in men with elevated plasma lycopene levels: results
of a prospective analysis. Cancer Res. 1999 Mar 15;59(6):1225-30.
6.) Giovannucci E, Ascherio A, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. ake
of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer
Inst. 1995 Dec 6;87(23):1767-76.
7.) Majewski S, Szmurlo A, Marczak M, Jablonska S, Bollag W.: Synergistic effect
of retinoids and interferon alpha on tumor-induced angiogenesis: anti-angiogenic
effect on HPV-harboring
tumor-cell lines.Int J Cancer. 1994 Apr 1;57(1):81-5.
8.) Pastorino U, Infante M, Maioli M, et al. Adjuvant treatment
of stage I lung cancer with high-dose vitamin A. J Clin Oncol 1993;11:1216–22.
Vitamin C
1.) Wybieralska E, Koza M, Sroka J, Czyz J, Madeja Z. Ascorbic acid inhibits the
migration of walker 256 carcinosarcoma cells. Cell Mol Biol Lett.
2008;13(1):103-11. Epub 2007 Oct 29.
2.) Hanck A. Vitamin C and cancer. Int J Vit Nutr Res 1983;(Suppl #24):87–104
[review].
3.) Murata A, Morishige F, Yamaguchi H. Prolongation of survival times of
terminal cancer patients by administration of large doses of ascorbate. Int J
Vit Nutr Res 1982;(Suppl #23):103–14.
4.) Bussey HJR, DeCosse JJ, Deschner EE, et al. A randomized trial of ascorbic
acid in polyposis coli. Cancer 1982;50:1434–9.
5.) Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of
cancer: reevaluation of prolongation of survival times in terminal human cancer.
Proc Natl Acad Sci USA 1978;75:4538–42.
6.) Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of
cancer: prolongation of survival times in terminal human cancer. Proc Natl Acad
Sci USA 1976;73:3685–9.
Selenium
1.) Li H, Stampfer MJ, Giovannucci EL, Morris JS, Willett WC,
Gaziano JM, Ma J.A prospective study of plasma selenium levels and prostate
cancer risk. J Natl Cancer Inst. 2004 May
5;96(9):696-703.
2.) Yu M-W, Horng I-S, Hsu K-H, et al. Plasma selenium levels and risk of
hepatocellular carcinoma among men with chronic hepatitis virus infection. Am J
Epidemiol 1999;150:367–74.
3.) Knekt P, Marniemi J, Teppo L, et al. Is low selenium status a risk factor
for lung cancer? 1998 Nov 15;148(10):975-82.
4.) Scieszka M, Danch A, Machalski M, Drozdz M. Plasma selenium concentration in
patients with stomach and colon cancer in the Upper Silesia. Neoplasma
1997;44:395–7.
5.) Toma S, Micheletti A, Giacchero A, et al. Selenium therapy in patients with
precancerous and malignant oral cavity lesions: preliminary results.Cancer
Detection Prev 1991;15:491–3.
6.) Knekt P, Aromaa A, Maatela J, et al. Serum selenium and subsequent risk of
cancer among Finnish men and women. J Natl Cancer Inst 1990;82:864–8.
7.) Burney PGJ, Comstock GW, Morris JS. Serologic precursors of cancer: serum
micronutrients and the subsequent risk of pancreatic cancer. Am J Clin Nutr
1989;49:895–900.
8.) Helzlsouer KJ, Comstock GW, Morris JS. Selenium, lycopene, alpha-tocopherol,
ß-carotene, retinol, and subsequent bladder cancer. Cancer Res 1989;49:6144–8.
9.) Jaskiewicz K, Marasas WF, Rossouw JE, et al. Selenium and other mineral
elements in populations at risk for esophageal cancer. Cancer 1988;62:2635–9.
10.) Medina D, Morrison DG. Current ideas on selenium as a
chemopreventative agent. Pathol Immunopathol Res 1988;7:187–99.
11.) Fex G, Pettersson B, Akesson B. Low plasma selenium as a risk factor for
cancer death in middle-aged men. Nutr Cancer 1987;10:221–9.
12.) Medina D. Mechanisms of selenium inhibition of tumorigenesis. Adv Exp Med
Biol 1986;206:465–72.
13.) Willett WC, Polk BF, Morris JS, et al. Prediagnostic serum Selenium and
risk of cancer. Lancet 1983;42:130–4.
14.) Beisel WR. Single nutrients and immunity. Am J Clin Nutr 1982;35:417–68.
15.) Shamberger RJ, Rukoven E, Lonfield AK, et al. Antioxidants and cancer.
Selenium in the blood of normals and cancer patients. J Natl Cancer Inst
1973;4:863–70.
Vitamin D
1.) Lappe J, Travers-Gustafson D, Davies K, Recker R, Heaney R. Vitamin D and
calcium supplementation reduces cancer risk: results of a randomized trial.
American Journal of Clinical Nutrition. Am J Clin Nutr. 2007 Jun;85(6):1586-91.
2.) Ma Y, et al. Study presented at the 2007 centennial meeting of the American
Association for Cancer Research (AACR), April 14 to 18, 2007, Los Angeles.
3.)Holick MF.: Vitamin D: Its role in cancer prevention and treatment. Prog
Biophys Mol Biol. 2006 Mar 10;
4.) Schwartz GG, Eads D, Rao A, Cramer SD, Willingham MC, Chen TC, Jamieson DP,
Wang L, Burnstein KL, Holick MF, Koumenis C.:Pancreatic cancer cells express
25-hydroxyvitamin D-1
alpha-hydroxylase and their proliferation is inhibited by the prohormone
25-hydroxyvitamin D3.Carcinogenesis. 2004 Jun;25(6):1015-26. Epub 2004 Jan 23.
5.) Wietrzyk J, Pelczynska M, Madej J, Dzimira S, Kusnierczyk H, Kutner A,
Szelejewski W, Opolski A.: Toxicity and antineoplastic effect of
(24R)-1,24-dihydroxyvitamin D3 (PRI-2191).Steroids. 2004 Sep;69(10):629-35.
6.) Vegesna V, O'Kelly J, Said J, Uskokovic M, Binderup L, Koeffle HP.: Ability
of potent vitamin D3 analogs to inhibit growth of prostate cancer cells in vivo.
Anticancer Res. 2003
Jan-Feb;23(1A):283-9.
7.) Grant WB. An estimate of premature cancer mortality in the U.S. due to
inadequate doses of solar ultraviolet-B radiation. Cancer. 2002 Mar
15;94(6):1867-75.
8.) Majewski S, Skopinska M, Marczak M, Szmurlo A, Bollag W, Jablonska S.:
Vitamin D3 is a potent inhibitor of tumor cell-induced angiogenesis. J Investig
Dermatol Symp Proc. 1996
Apr;1(1):97-101.
9.) James SY, Mackay AG, Colston KW. Effects of 1,25 dihydroxyvitamin D3 and its
analogues on induction of apoptosis in breast cancer cells. J Steroid Biochem
Mol Biol. 1996
Jul;58(4):395-401.
10.) Schwartz GG, Hill CC, Oeler TA, Becich MJ, Bahnson
RR.1,25-Dihydroxy-16-ene-23-yne-vitamin D3 and prostate cancer cell
proliferation in vivo. Urology. 1995 Sep;46(3):365-9.
11.) Majewski S, Szmurlo A, Marczak M, Jablonska S, Bollag W.: Inhibition of
tumor cell-induced angiogenesis by retinoids, 1,25-dihydroxyvitamin D3 and their
combination.Cancer Lett. 1993
Nov 30;75(1):35-9.
Omega 3 Essential Fatty Acids
1.) Colomer R, Moreno-Nogueira JM, García-Luna PP, García-Peris
P, García-de-Lorenzo A, Zarazaga A, Quecedo L, del Llano J, Usán L, Casimiro C.
N-3 fatty acids, cancer and cachexia: a systematic review of the literature. Br
J Nutr. 2007 May;97(5):823-31.
2.) Zhang W, Long Y, Zhang J, Wang C. Modulatory effects of EPA and DHA on
proliferation and apoptosis of pancreatic cancer cells. J Huazhong Univ Sci
Technolog Med Sci. 2007 Oct;27(5):547-50.
3.) Dauchy RT, Dauchy EM, Davidson LK, Krause JA, Lynch DT, Tirrell PC, Tirrell
RP, Sauer LA, Van der Riet P, Blask DE. Inhibition of fatty acid transport and
proliferative activity in tissue-isolated human squamous cell cancer xenografts
perfused in situ with melatonin or eicosapentaenoic or conjugated linoleic
acids. Comp Med. 2007 Aug;57(4):377-82.
4.) Chen J, Power KA, Mann J, Cheng A, Thompson LU. Flaxseed alone or in
combination with tamoxifen inhibits MCF-7 breast tumor growth in ovariectomized
athymic mice with high circulating levels of estrogen. Exp Biol Med (Maywood).
2007 Sep;232(8):1071-80.
5.) Kolar SS, Barhoumi R, Callaway ES, Fan YY, Wang N, Lupton JR,
Chapkin RS. Synergy between docosahexaenoic acid and butyrate elicits
p53-independent apoptosis via mitochondrial Ca(2+) accumulation in colonocytes.
Am J Physiol Gastrointest Liver
Physiol. 2007 Nov;293(5):G935-43. Epub 2007 Aug 23.
6.) Kato T, Kolenic N, Pardini RS. Docosahexaenoic acid (DHA), a primary tumor
suppressive omega-3 fatty acid, inhibits growth of colorectal cancer independent
of p53 mutational status. Nutr Cancer. 2007;58(2):178-87.
7.) Espada CE, Berra MA, Martinez MJ, Eynard AR, Pasqualini ME. Effect of Chia
oil (Salvia Hispanica) rich in omega-3 fatty acids on the eicosanoid release,
apoptosis and T-lymphocyte tumor infiltration in a murine mammary gland
adenocarcinoma. Prostaglandins Leukot Essent Fatty Acids. 2007 Jul;77(1):21-8.
Epub 2007 Jul 6.
8.) Saarinen NM, Power K, Chen J, Thompson LU. Flaxseed attenuates the tumor
growth stimulating effect of soy protein in ovariectomized athymic mice with
MCF-7 human breast cancer xenografts. Int J Cancer. 2006 Aug 15;119(4):925-31.
9.) Shirota T, Haji S, Yamasaki M, Iwasaki T, Hidaka T, Takeyama Y, Shiozaki H,
Ohyanagi H. Apoptosis in human pancreatic cancer cells induced by
eicosapentaenoic acid. Nutrition. 2005
Oct;21(10):1010-7.
10.) Schley PD, Jijon HB, Robinson LE, Field CJ. Mechanisms of omega-3 fatty
acid-induced growth inhibition in MDA-MB-231 human breast cancer cells. Breast
Cancer Res Treat. 2005
July;92(2):187-95.
11.) de Deckere EA. Possible beneficial effect of fish and fish
n-3 polyunsaturated fatty acids in breast and colorectal cancer. Eur J Cancer
Prev. 1999 Jul;8(3):213-21.
12.) Chang WL, Chapkin RS, Lupton JR. Fish oil blocks azoxymethane-induced rat
colon tumorigenesis by increasing cell differentiation and apoptosis rather than
decreasing cell
proliferation. J Nutr. 1998 Mar;128(3):491-7.
13.) Bagga D, Capone S, Wang HJ, Heber D, Lill M, Chap L, Glaspy JA. Dietary
modulation of omega-3/omega-6 polyunsaturated fatty acid ratios in patients with
breast cancer. J Natl Cancer Inst. 1997 Aug 6;89(15):1123-31.
Di-indolymethanes (DIM, IC3)
1.) Moiseeva EP, Almeida GM, Jones GD, Manson MM.Extended treatment with
physiologic concentrations of dietary phytochemicals results in altered gene
expression, reduced growth, and apoptosis of cancer cells. Mol Cancer Ther. 2007
Nov;6(11):3071-9.
2.) Weng JR, Tsai CH, Kulp SK, Wang D, Lin CH, Yang HC, Ma Y, Sargeant A, Chiu
CF, Tsai MH, Chen CS. A potent indole-3-carbinol derived antitumor agent with
pleiotropic effects on multiple signaling pathways in prostate cancer cells.
Cancer Res. 2007 Aug
15;67(16):7815-24.
3.) Pappa G, Strathmann J, Löwinger M, Bartsch H, Gerhäuser C. Quantitative
combination effects between sulforaphane and 3,3'-diindolylmethane on
proliferation of human colon cancer cells in vitro. Carcinogenesis. 2007
Jul;28(7):1471-7. Epub 2007 Feb 28.
4.) Pappa G, Lichtenberg M, Iori R, Barillari J, Bartsch H, Gerhäuser C.
Comparison of growth inhibition profiles and mechanisms of apoptosis induction
in human colon cancer cell lines
by isothiocyanates and indoles from Brassicaceae. Mutat Res. 2006 Jul
25;599(1-2):76-87. Epub 2006 Feb 24.
5.) Bhuiyan MM, Li Y, Banerjee S, Ahmed F, Wang Z, Ali S, Sarkar FH.
Down-regulation of androgen receptor by 3,3'-diindolylmethane contributes to
inhibition of cell proliferation and induction of apoptosis in both
hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells. Cancer Res.
2006 Oct 15;66(20):10064-72.
6.) Aggarwal BB, Ichikawa H. Molecular targets and anticancer potential of
indole-3-carbinol and its derivatives. Cell Cycle. 2005 Sep;4(9):1201-15. Epub
2005 Sep 6.
7.) Chinni SR, Li Y, Upadhyay S, Koppolu PK, Sarkar FH. Indole-3-carbinol (I3C)
induced cell growth inhibition, G1 cell cycle arrest and apoptosis in prostate
cancer cells. Oncogene. 2001
May 24;20(23):2927-36.
8.) Cover CM, Hsieh SJ, Cram EJ, et al. Indole-3-carbinol and tamoxifen
cooperate to arrest the cell cycle of MCF-7 human breast cancer cells. Cancer
Res 1999;59:1244–51.
Turmeric (Curcumin)
1.) Ji C, Cao C, Lu S, Kivlin R, Amaral A, Kouttab N, Yang H, Chu W, Bi Z, Di W,
Wan Y. Curcumin attenuates EGF-induced AQP3 up-regulation and cell migration in
human ovarian cancer cells.Cancer Chemother Pharmacol. 2008 Jan 23 [Epub ahead
of print].
2.) Steward WP, Gescher AJ. Curcumin in cancer management: Recent results of
analogue design and clinical studies and desirable future research. Mol Nutr
Food Res. 2008 Jan 9 [Epub ahead of print].
3.) Shankar S, Ganapathy S, Chen Q, Srivastava RK. Curcumin sensitizes
TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and
angiogenesis. Mol Cancer. 2008 Jan 29;7(1):16 [Epub ahead of print]
4.) Moiseeva EP, Almeida GM, Jones GD, Manson MM. Extended treatment with
physiologic concentrations of dietary phytochemicals results in altered gene
expression, reduced growth, and apoptosis of cancer cells. Mol Cancer Ther. 2007
Nov;6(11):3071-9.
5.) Shankar S, Chen Q, Sarva K, Siddiqui I, Srivastava RK. Curcumin enhances the
apoptosis-inducing potential of TRAIL in prostate cancer cells: molecular
mechanisms of apoptosis, migration and angiogenesis. J Mol Signal. 2007 Oct
4;2:10.
6.) Shankar S, Srivastava RK. Bax and Bak genes are essential for maximum
apoptotic response by curcumin, a polyphenolic compound and cancer
chemopreventive agent derived from turmeric, Curcuma longa. Carcinogenesis. 2007
Jun;28(6):1277-86. Epub 2007 Feb 2.
7.) Shankar S, Srivastava RK. Involvement of Bcl-2 family members,
phosphatidylinositol 3'-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced
apoptosis in prostate cancer. Int J Oncol. 2007 Apr;30(4):905-18.
8.) Somers-Edgar TJ, Scandlyn MJ, Stuart EC, Le Nedelec MJ, Valentine SP,
Rosengren RJ. The combination of epigallocatechin gallate and curcumin
suppresses ERalpha-breast cancer cell growth in vitro and in vivo. Int J Cancer.
2007 Dec 20 [Epub ahead of print].
9.) Chen A, Xu J, Johnson AC. Curcumin inhibits human colon cancer cell growth
by suppressing gene expression of epidermal growth factor receptor through
reducing the activity of the transcription factor Egr-1. Oncogene. 2006 Jan
12;25(2):278-87.
10.) Wahl H, Tan L, Griffith K, Choi M, Liu JR. Curcumin enhances
Apo2L/TRAIL-induced apoptosis in chemoresistant ovarian cancer cells. Gynecol
Oncol. 2007 Apr;105(1):104-12. Epub 2006 Dec 15.
11.) Chen J, Wanming D, Zhang D, Liu Q, Kang J.Water-soluble antioxidants
improve the antioxidant and anticancer activity of low concentrations of
curcumin in human leukemia cells. Pharmazie. 2005 Jan;60(1):57-61.
12.) Deeb DD, Jiang H, Gao X, Divine G, Dulchavsky SA, Gautam SC.
Chemosensitization of hormone-refractory prostate cancer cells by curcumin to
TRAIL-induced apoptosis. J Exp Ther Oncol. 2005;5(2):81-91.
13.)Dobrovolskaia MA, Kozlov SV.: Inflammation and cancer: when NF-kappaB
amalgamates the perilous partnership. Curr Cancer Drug Targets. 2005
Aug;5(5):325-44.
14.) Deeb D, Jiang H, Gao X, Hafner MS, Wong H, Divine G, Chapman RA, Dulchavsky
SA, Gautam SC. Curcumin sensitizes prostate cancer cells to tumor necrosis
factor-related apoptosis-inducing gand/Apo2L by inhibiting nuclear factor-kappaB
through suppression of IkappaBalpha phosphorylation. Mol Cancer Ther. 2004
Jul;3(7):803-12.
15.) Van Erk MJ, Teuling E, Staal YC, Huybers S, Van Bladeren PJ, Aarts JM, Van
Ommen B. Time- and dose-dependent effects of curcumin on gene expression in
human colon cancer cells. J Carcinog. 2004 May 12;3(1):8.
16.)Ernst P.: The role of inflammation in the pathogenesis of gastric cancer.
Aliment Pharmacol Ther. 1999 Mar;13 Suppl 1:13-8
17.) Menon LG, Kuttan R, Kuttan G. Anti-metastatic activity of curcumin and
catechin. Cancer Lett 1999;141:159–65.
18.) Khafif A, Schantz SP, Chou TC, Edelstein D, Sacks PG. uantitation of
chemopreventive synergism between (-)-epigallocatechin-3-gallate and curcumin in
normal, premalignant
and malignant human oral epithelial cells. Carcinogenesis. 1998
Melatonin
1.) Lissoni P, Barni S, Mandalŕ, et al. Decreased toxicity and increased
efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic
solid tumour patients with poor clinical status. Eur J Cancer 1999;35:1688–92.
2.) Lissoni P, Cazzanga M, Tancini G, et al. Reversal of clinical resistance to
LHRH analogue in metastatic prostate cancer by the pineal hormone melatonin:
efficacy of LHRH analogue plus melatonin in patients progressing on LHRH
analogue alone. Eur Urol 1997;31:178–81.
3.) Lissoni P, Paolorossi F, Tancini G, et al. Is there a role for melatonin in
the treatment of neoplastic cachexia? Eur J Cancer 1996;32A:1340–3.
4.) Lissoni P, Paolorossi F, Tancini G, et al. A phase II study of tamoxifen
plus melatonin in metastatic solid tumour patients. Br J Cancer 1996;74:1466–8.
5.) Lissoni P, Brivio O, Brivio F, et al. Adjuvant therapy with the pineal
hormone melatonin in patients with lymph node relapse due to malignant melanoma.
J Pineal Res 1996;21:239–42.
6.) Lissoni P, Barmo S. Meregalli S, et al. Modulation of cancer endocrine
therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic
breast cancer patients progressing under tamoxifen alone. Br J Cancer
1995;71:854–6.
7.) Reiter RJ, Melchiorri D, Sewerynek E, Poeggeler B, Barlow-Walden L, Chuang
J, Ortiz GG, Acuna-Castroviejo D.: A review of the evidence supporting
melatonin's role as an antioxidant.J
Pineal Res. 1995 Jan;18(1):1-11.
8.) Neri B, Fiorelli C, Moroni F, et al. Modulation of human lymphoblastoid
interferon activity by melatonin in metastatic renal cell carcinoma. Cancer
1994;73:315–9.
9.) Lissoni P, Barni S, Cazzaniga M, Ardizzoia A, Rovelli F, Brivio F, Tancini
G.: Efficacy of the concomitant administration of the pineal hormone melatonin
in cancer immunotherapy with low-dose IL-2 in patients with advanced solid
tumors who had progressed on IL-2 alone. Oncology. 1994 Jul-Aug;51(4):344-7.
10.) Lissoni P, Barni S, Ardizzoia A, et al. A randomized study with the pineal
hormone melatonin versus supportive care alone in patients with brain metastases
due to solid neoplasms. Cancer 1994;73:699–701.
11.) Lissoni P, Barni S, Tancini G, et al. A randomised study with subcutaneous
low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone
melatonin in advanced solid neoplasms other than renal cancer and melanoma. Br J
Cancer 1994;69:196–9.
12.) Aldeghi R, Lissoni P, Barni S, et al. Low-dose interlekin-2 subcutaneous
immunotherapy in association with the pineal hormone melatonin as a first-line
therapy in locally advanced or metastatic hepatocellular carcinoma. Eur J Cancer
1994;30A:167–70.
13.) Lissoni P, Brivio F, Ardizzoia A, et al. Subcutaneous therapy with low-dose
interlekin-2 plus the neurohormone melatonin in metastatic gastric cancer
patients with low performance status.
Tumori 1993;79:401–4.
14.) Lissoni P, Barni S, Ardizzoia A, et al. Randomized study with the pineal
hormone melatonin versus supportive care alone in advanced nonsmall cell lung
cancer resistant to a first-line
chemotherapy containing cisplatin. Oncology 1992;49:336–9.
15.) Lissoni P, Barni S, Crispino S, et al. Endocrine and immune effects of
melatonin therapy in metastatic cancer patients. Eur J Cancer Clin Oncol
1989;25:789–95. |
